Company intelligence / Profile preview

Immugenyx

New York City, New York, United States

Ownership: Private
Development stage: Other

Overview

Immugenyx, a subsidiary of Hemogenyx Pharmaceuticals, is involved in the development of humanized mouse models for drug discovery and disease modeling (noting a partnership with Janssen for SLE). Hemogenyx (with participation by Immugenyx) has advanced a CAR-T cell therapy for relapsed/refractory acute myeloid leukemia to Phase 1 trials, with ongoing recruitment and initial safety/efficacy data in adults showing positive trends[3][4][7].

Therapeutic areas: OncologyHematologyImmunology
Modalities: Cell therapyCAR-T cell therapyHumanized mouse models
Industry: Biotech

Partnerships

Janssen (Johnson & Johnson)Kure.aiMade Scientific (as CDMO)

Beyond the preview

Go deeper on Immugenyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immugenyx.

Explore the full profile